Processes for preparation of Marek's disease virus using continuous avian cell lines

• US 6,410,297 B1
• Filed: 11/19/1999
• Issued: 06/25/2002
• Est. Priority Date: 12/09/1998
• Status: Expired due to Fees

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: Rong, Sing, Sheppard, Michael G.
• Primary Examiner(s): Navarro, Mark
• Assistant Examiner(s): BASKAR, PADMAVATHI
• Application Number:
  US09/443,800
• Time in Patent Office: 949 Days
• Field of Search: 435/235.1, 435/237, 435/239, 435/320.1, 435/349, 435/325, 435/240, 435/172.3, 435/240.2, 424/229.1, 424/93.21, 424/93.1, 514/44, 536/23.1, 536/23.72, 536/27
• US Class Current: 435/235.1
• CPC Class Codes: A61K 2039/525 Virus
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/255 Marek's disease virus
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/16343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/16351 Methods of production or purification of viral material
• CPC Class Codes: C12N 2710/16361 Methods of inactivation or attenuation
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention relates to avian cell lines which efficiently support the growth and productive infection of Marek'"'"'s Disease Virus at high titers. The present invention also relates to avian cell lines which have been engineered to support the growth and productive infection of recombinant Marek'"'"'s Disease Virus at high titers. The present invention relates a process for the preparation of Marek'"'"'s Disease Virus in quantities suitable for vaccine purposes.

Claims

1. A method for producing a Marek'"'"'s Disease serotype 1, serotype 2 and serotype 3 virus (MDV), wherein said Marek'"'"'s Disease virus is a wild-type or naturally occurring mutant viral particle, or a recombinant viral particle, which comprises culturing a continuous quail muscle myoblast cell line QM7 which is infected or transfected with nucleotide sequences encoding the MDV.

2. The method of claim 1 wherein the nucleotide sequences encode a naturally ccurring MDV.

3. The method of claim 1 wherein the nucleotide sequences encode a recombinant MDV.

4. The method of claim 3 wherein the MDV is a recombinant molecule comprising the nucleic acid sequence of MDV and at least one heterologous gene inserted into said nucleic acid sequence of MDV.

5. The method of claim 3 wherein the MDV is a recombinant molecule comprising the nucleic acid sequence of MDV from which one or more genes, regulatory genetic elements, has been deleted.

6. The method of claim 5 wherein the deleted gene is essential for replication.

7. The method of claim 6 wherein the deleted gene is gH.

8. The method of claim 1 wherein the MDV is a virus used for the preparation of a vaccine capable of inducing protection against disease in avians.

9. The method of claim 1 wherein the MDV is MDV- 1 strain 652.

10. The method of claim 9 wherein the cell line is ATCC CRL-12600.

11. The method of claim 1, wherein the QM7 cell line is ATCC CRL-12599.